MyVisionLenses

UK Patent Offer

 

Introduction 

Only within the United Kingdom more than 1,5 million patients could profit by this invention and the therapeutic result. 

The basic principle of this therapeutic method is called ‚Add-on therapy ‘, which means that the patient wears the lenses permanently - in addition to regular MD or Cataract disease treatment.  

 

The ‚UVA-,UVB-,UVC- and HEV Blocking Contact Lenses’s mechanism works through absorbing the visual spectrum of UVA-(315-380nm), UVB-(280-315nm), UVC(100-280nm) radiation. 

Unfiltered can this radiation cause a state decomposition and degeneration of retinal cells.

This was proofed lately within mayor medical studies.

 

Mr. Green’s patented lenses (application number: GB1910820.8, published at ‚The Patents Journal 11 September 2019 No. 6799) can absorb at least 99.7% of this radiation.

 

 Portfolio

 

Further Information

The patent offer is listed by the Allied Security Trust (AST).

The patent is named

„UV-A, UV-B, UV-C & HEV Blocking Contact Lenses“

and is filed under the UK Application Number: GB1910820.8.

For further information please contact AST.

 

Contact

Join our mailing list

info@myvisionlenses.co.uk

Tel:  +44 20 3807 5192

 

160 Kemp House
City Road
London
EC1V 2NX